NLRP3i (16673-34-0) is an NLRP3 inflammasome inhibitor which likely acts via interfering with the formation of the NLRP3 inflammasome complex and which exhibits promising?in vivo?protective activities in mouse acute myocardial infarction models. It blocks ASC aggregation, blocks the release of IL-1β and the activation of caspase-1 in macrophages expressing constitutively active NLRP3 but does not directly inhibit caspase-1.1,2?Limits infarct size after myocardial ischemia-reperfusion as well as leukocyte infiltration in a peritonitis model in mice.2
An impurity arising in the synthesis of Glyburide (G598350).
5-Chloro-2-methoxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide is an organic building block. It has been reported as an intermediate in the synthesis of glyburide. Synthesis of 5-chloro-2-methoxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide has been reported.
1) Fulp?et al.?(2018),?Structural Insights of Benzenesulfonamide Analogues as NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization; J. Med. Chem.,?61?5412
2) Marchetti?et al.?(2014),?A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse; J. Cardiovas. Pharmacol.,?63?316
